Matthew Thompson

Matthew Thompson is a General Partner at Enhanced Healthcare Partners (EHP), the healthcare-dedicated private equity firm founded in 2005 that was previously known as Enhanced Equity Funds. He sits on the firm's investment committee and is responsible for sourcing, evaluating, executing, and managing investments, with more than 15 years of experience in healthcare mergers and acquisitions. He has risen through the firm: he joined Enhanced Equity Funds as a Vice President (announced February 2014) and is now one of the firm's named General Partners alongside co-founder Malcolm Kostuchenko and Samarth Chandra.

Before Enhanced, Thompson was a Vice President / Director at Riverside Partners, a Boston-based private equity firm focused on healthcare and technology. Earlier, he worked in corporate development and corporate strategy at CVS Caremark (CVS Health), a Fortune-15 company, where he helped lead work across pharmacy, senior living, disease management, health-care IT, wellness, and medical clinics. He began his career as a consultant at Monitor Group (now Monitor Deloitte), managing growth-oriented and M&A projects across a range of industries.

Thompson holds a Bachelor of Science from Georgetown University, where he majored in Finance and Operations Management. Through his EHP role he has held multiple board seats, currently including Hallmark Health Care Solutions and Pryor Health, and previously including Eventus WholeHealth, Pharmaceutical Associates, Inc. (PAI), and SCA Pharmaceuticals.

• Invests exclusively in healthcare, targeting lower-middle-market companies across care delivery/services, healthcare IT, pharmacy, and life-science/pharma services.
• The firm describes its approach as "value creation through organizational development, culture and growth," partnering with founder- and family-run businesses rather than pursuing financial-engineering plays.
• Flexible transaction types: growth equity, recapitalizations, management buyouts, acquisition-led ("buy-and-build") strategies, and founder-led capital solutions — control or structured minority.
• Check size of roughly $25–$75 million+ over the life of a company, with a stated preference for conservative leverage and a ~5-year hold.
• Looks for companies with clinical, strategic, technological, and cultural differentiation and strong organic growth potential.
• Thompson's personal sweet spot reflects his career: niche, reimbursement-driven healthcare and pharmacy/pharma-services businesses, drawing on his CVS Caremark and healthcare-M&A background.